Abstract
INTRODUCTION:
The opioid epidemic has exacted a significant toll in rural areas, yet adoption of medications for opioid use disorder (MOUD) lags. The Rural Access to Medication Assisted Treatment in Pennsylvania (RAMP) Project facilitated adoption of MOUD in rural primary care clinics. The purpose of this study was to gain a better understanding of the barriers and facilitators operating at multiple levels to access or provide MOUD in rural Pennsylvania.
METHODS:
In total, 35 semi-structured interviews were conducted with MOUD patients and MOUD providers participating in RAMP. Qualitative analysis incorporated both deductive and inductive approaches. Interviews were coded and thematic analysis was performed. Using a modified social ecological framework, themes from the qualitative interviews are organized in five nested levels: individual, interpersonal, healthcare setting, community, and public policy.
RESULTS:
Patients and providers agreed on many barriers (e.g., lack of providers, lack of transportation, insufficient rapport and trust in patient-provider relationship, and cost, etc.); however, their interpretation of the barrier, or indicated solution, diverged in meaningful ways. Patients described their experiences in broad terms pointing to the social determinants of health, as they highlighted their lives outside of the therapeutic encounter in the clinic. Providers focused on their professional roles, responsibilities, and operations within the primary care setting.
CONCLUSIONS:
Providers may want to discuss barriers to treatment related to social determinants of health with patients, and pursue partnerships with organizations that seek to address those barriers. The findings from these interviews point to potential opportunities to enhance patient experience, increase access to and optimize processes for MOUD in rural areas, and reduce stigma against people with opioid use disorder (OUD) in the wider community.
Keywords: Medications for Opioid Use Disorder (MOUD), Qualitative Research, Rural, Primary Care, Stigma
1.0. Introduction
The standard of care for opioid use disorder (OUD) treatment is the use of buprenorphine, naltrexone, and/or methadone, collectively known as medication treatment for OUD (MOUD) (SAMHSA, 2021). In the United States, policies have created access barriers to buprenorphine and methadone medications, including limits on which providers may prescribe or dispense buprenorphine and methadone (Joudrey et al., 2021; Joudrey and Gordon, 2021) and how often patients must travel to the provider to receive MOUD (Gordon et al., 2020; Perry et al., 2022).
To increase access to MOUD, government agencies have turned to primary care providers (PCPs), who are often the usual source of care for many health needs (Gordon et al., 2020). However, adoption of MOUD in rural primary care has been lagging. Across all US counties, 33% lack a buprenorphine prescriber; among rural counties, 57% lack a prescriber (MODRN et al., 2021). A recent systematic review of rural-specific barriers to MOUD concluded that it is unknown if access to naltrexone in rural areas is similar to buprenorphine (Lister et al. 2020). Methadone cannot be dispensed by PCPs and is often only accessible via long distances from rural communities, as few opioid treatment programs (OTPs) are located in rural communities (Joudrey et al., 2019). More widespread adoption of MOUD by rural PCPs is necessary to improve access and subsequent outcomes for these patients.
Previous research has explored barriers and facilitators to providing and receiving MOUD from the provider perspective. Providers have reported barriers such as lack of MOUD prescribers, inadequate access or coordination with behavioral health services, lack of training in treating addiction, stigma towards patients with addiction, a concern of their office being overwhelmed with patients with addiction if they offer MOUD, resistance from practice partners, and lack of adequate funding/reimbursement for MOUD from payers (Andraka-Christou & Capone, 2018; Andrilla et al., 2019; Browne et al., 2016; Cole et al., 2019; Hutchinson et al., 2014; LaBelle et al., 2016; Molfenter et al., 2019; Oros et al., 2021). In other studies, patients have reported barriers including the challenges of cravings and withdrawal, disruption of treatment due to criminal justice involvement, perceived stigma against them, treatment program inflexibility, no previous positive experience with MOUD, screenings reflecting a perceived lack of trust from providers, cost of care, economic insecurity, and related unmet social needs (Bunting et al., 2018; Saunders et al., 2019; Snell-Rood et al., 2021; Tofighi et al., 2019; Truong et al., 2019). Providers have reported facilitators for prescribing MOUD, including continuity of patient care and positive perceptions of buprenorphine (Barry et al., 2009). Patients identified receiving support from peers, family, and providers as well as incorporating patient preference into treatment for OUD as facilitators (Mackey et al., 2009; Saunders et al., 2020)
This article contributes an analysis of both patient and provider experiences with MOUD provision within primary care in rural areas. Project Rural Access to MAT1 in Pennsylvania (RAMP) sought to increase the number of primary care physicians (PCPs) delivering high-quality MOUD in rural Pennsylvania by implementing and testing a state-led, multi-faceted intervention. This intervention primarily focused on Medicaid enrollees, in whom rates of MOUD have increased in recent years, but remain low (MODRN et al., 2021). The purpose of this article is to present results on the barriers and facilitators operating at multiple levels as both patients and providers navigate their interpersonal relationships, the organizations in which they participate, and their wider communities to access or provide OUD treatment. In this article, we apply a modified social ecological framework (Baron et al., 2014; McLeroy et al., 1988; Stokols, 1992) to identify the challenges and opportunities in improving access to MOUD in rural Pennsylvania at individual, interpersonal, healthcare setting, community, and policy levels.
No study to our knowledge has explored perceived barriers to MOUD from both patients and providers in the same area or part of the same intervention designed to increase access to MOUD. Understanding where the perceptions of these two groups intersect may be informative for two primary reasons. First, patients and providers may agree on many barriers (e.g., lack of providers, lack of transportation, insufficient rapport and trust in patient-provider relationship, and cost, etc.); however, their interpretation of the barrier, or indicated solution, might diverge in meaningful ways. Second, patients and providers might disagree or may not acknowledge specific barriers that are salient to the other, which could inform future efforts to build alliances amongst providers and patients to address shared systemic barriers as well as advance awareness of barriers particular to patients or providers.
2.0. Methods
2.1. Setting
Project RAMP was an Agency for Healthcare Research and Quality (AHRQ) funded demonstration and dissemination project that recruited 26 primary care clinics in 13 rural Pennsylvania counties where OUD prevalence and opioid overdose rates were above the national average (Cole et al., 2021; Nourjah & Kato, 2021). The 26 clinics received support in adopting and sustaining MOUD practices (i.e., buprenorphine and naltrexone) via an implementation team that also established relationships with local care management and treatment organizations, and assisted clinics in improving their quality of MOUD, behavioral health, and care management provision. Project RAMP also included online education modules, peer-to-peer teleconsultation, and partnerships with Medicaid managed care organizations (Cochran et al., 2019). Of the 26 clinics, 23 prescribed MOUD during the project study period. 15 sites prescribed buprenorphine and 20 prescribed naltrexone. 12 sites prescribed both forms of MOUD, 3 only prescribed buprenorphine, and 8 only prescribed naltrexone. A total of 328 patients were treated with buprenorphine and another 146 patients were treated with naltrexone during the study period. Due to data collection issues, these numbers are likely undercounts of the total number of patients treated. No prescribers were prescribing to their DATA 2000 Waiver limit, to our knowledge. All providers interviewed treated patients with MOUD. However, not all PCPs at each practice prescribed MOUD. In some cases, one PCP would be the primary MOUD prescriber at a given clinic. The patients and providers interviewed in this study either were employed by or received MOUD treatment from a primary care clinic that participated in Project RAMP. This present study, which was focused on the barriers and facilitators of MOUD in rural primary care settings, was a secondary aim to the primary project aim of implementing and evaluating Project RAMP.
2.2. Recruitment
The implementation team delivered recruitment packets to all RAMP practices to distribute to patients to inform them about the opportunity to participate in interviews. The packets included a one-page document explaining the study goals, benefits, and risks to participating, and instructions to fill out and mail an accompanying form with contact information. The packets included an addressed and stamped envelope to the study team, as well as a gift card that could be activated upon completion of the interview. The implementation team instructed providers to distribute the recruitment packets to patients who received MOUD from their practices. To participate in the study, patients had to be over 18 years old, Medicaid recipients, formally diagnosed with OUD, and must have received MOUD from a participating provider. Interested patients completed forms and mailed them to the Evaluation Institute at the University of Pittsburgh. All patients who met the inclusion criteria and who were successfully contacted were included. No patients dropped out during the interviews. Researchers at the Evaluation Institute then arranged interviews with patients who completed the forms. Providers were recruited by the implementation team as part of the team’s regular contact with the providers. The implementation team worked to schedule interviews between the providers and the researchers. We interviewed providers from 20 of the 26 implementation sites. The six sites that did not participate were not responsive to scheduling requests. No providers dropped out during the interviews. All patients and providers who participated in interviews were remunerated with gift cards to honor their time.
2.3. Data Collection
The interviews were conducted by two research staff (Foulds and Taber) with training in qualitative methodology. The data collectors had no prior relationships with study participants. The data collectors conducted semi-structured interviews with nine patients and 27 providers to better understand the barriers and facilitators they experienced while providing or receiving MOUD in rural primary care settings in Pennsylvania. The interview protocols were designed by the study team, which included addiction treatment specialists, primary care providers, health services researchers, qualitative researchers, and the intervention’s implementation team. The interview protocols were designed primarily to capture evaluative information about the intervention, but included interview topics that were able to capture broader themes related to providing and receiving MOUD. Both the patient and provider interview guides were pilot tested.
2.4. Data Analysis
Interviews were recorded and transcribed. Transcripts of the interviews were imported into NVivo 12 for data management and analysis. The transcripts contained no identifying information and were labeled with an alphanumeric ID to preserve the confidentiality of participants. All electronic data were encrypted and password-protected and access was limited to the team members conducting analyses.
Analysis incorporated both deductive and inductive approaches. During an initial process of open-coding the transcripts, a codebook was created with both emergent codes along with a priori codes. Two qualitative data analysts (Bridges and Taber) independently coded the same three transcripts in their entirety while creating annotations and memos on emergent themes. The two coders convened meetings to discuss agreement and disagreement in coding applications across the three transcripts and the codebook was subsequently refined. Once the two coders achieved a 0.81 Cohen’s kappa score for intercoder reliability (Bernard, 2017), calculated in NVivo, independent coding of the remaining transcripts commenced. Regular meetings were held to discuss code applications. Thematic analysis was performed to identify, analyze, and interpret patterns in the data (Braun & Clarke, 2006; Chapman et al., 2015). When disagreements occurred regarding coding applications or interpretations of themes, the two qualitative data analysts met with a third researcher (Foulds) and discussed until consensus was obtained.
This study was approved by the University of Pittsburgh’s Institutional Review Board for human subjects and complied with all ethical standards and participant consent requirements.
3.0. Results
From December 2018 through June 2020, nine semi-structured interviews were conducted with people who received MOUD in RAMP participating clinics. Seven out of the nine MOUD patients were receiving naltrexone, and two out of the nine MOUD patients were prescribed buprenorphine. All patient interviews took place over the phone with a single interviewer (Foulds). The interviews ranged in length from 32 to 50 minutes. The average duration of the patient interviews was 40 minutes.
26 semi-structured interviews were conducted with 27 providers and staff working in 20 Project RAMP participating clinics. The professional roles of provider interviewees included MDs, DOs, nurse practitioners, physician assistants, medical assistants, nurses, practice managers, counselors, network directors, care management support specialists, development officers, and administrative staff. The provider interviews were conducted from April 2019 through May 2020, taking place in-person or remotely through Zoom. One or two interviewers (Foulds and Taber) were present at each interview. The shortest interview was 22 minutes, while the longest was 1 hour and 22 minutes. The average duration of the provider interviews was 47 minutes.
Using a modified social ecological framework, themes from the qualitative interviews are arranged in five nested levels: individual (e.g., knowledge, skills, attitudes), interpersonal (e.g., families, friends, social networks), healthcare setting (e.g., dynamics in the primary care practice setting), community (e.g., relationships among organizations and factors in the wider community), and public policy (e.g., local, state, and national laws and regulations).
Findings on barriers to treatment for people with OUD, including the provision and receipt of MOUD, in rural primary care settings are presented first. Then, we present findings on the facilitators for OUD treatment in rural primary care settings. In both of these sections, we juxtapose patients’ responses to those of the providers. Illustrative quotes for each theme from both patients and providers, organized by the modified social ecological framework, appear in Table 1 (barriers) and Table 2 (facilitators) and may be read alongside each subsection of results.
Table 1:
Representative quotes of barriers for receiving and providing MOUD
| Individuals’ Barriers | |||
|---|---|---|---|
| Patients’ Individual Barriers | Patient Quotes | Providers’ Individual Barriers | Provider Quotes |
| Ambivalence of ceasing opioid use | “You have to want to get clean. If you don’t want to get clean, you’re not going to. There is nothing anybody can do. People have been trying for centuries, ever since opiates came out…It’s because if you don’t want to get clean, you’re not going to get clean.” (Patient not currently receiving MOUD, but who was previously prescribed naltrexone, methadone, and buprenorphine) | Absence of formal training about addiction treatment | “The knowledge gap. I don’t have a lot of training in addiction. Conceptually, I wanted to approach this as a family doc and I wanted to do this as a family doc. And oftentimes, people who enter this, they know the importance, and understand the need for it, and they will become an addiction specialist. And I really wanted to do this as part of just what I do as a family doc. So, one of the barriers is that I didn’t have a lot of knowledge. I didn’t have a lot of training in addiction. So, I have to seek extra education about addiction and substance use disorders.” (MOUD provider, MD) |
| Felt stigma | “The one Suboxone place we do have is hidden back in a little nook by the pharmacy. In our town, when you go to drug and alcohol counseling, everybody knows that’s for drug and alcohol counseling. When you go to that little nook there, everybody knows that’s for Suboxone. You feel like you have to put your hood up, because there’s only one place you can get it.” (Patient not currently receiving MOUD, but who was previously prescribed naltrexone, methadone, and buprenorphine) | MOUD initiation reluctance | “I haven’t done Suboxone induction here…We were doing Suboxone induction in-house at [former practice], and that could be a potential barrier, so we decided we weren’t going to do that here…There’s always that hesitation because you don’t have that comfort level with it.” (MOUD provider, MD) |
| Stigmatized views about buprenorphine and methadone | “I do really believe that [naltrexone] is a great thing. And like coming from a person that did opiates for years, I would truly rather see people try Vivitrol before Suboxone or Methadone. Because I have tried them myself, just like I bought them on the street. I didn’t go to a doctor. And I do really think they are just like narcotics and drugs.” (Patient receiving naltrexone) | Unrecognized stigma | “I don’t think personally for our office stigma has been an issue. But stigma is everywhere, even if you don’t realize it. I’m sure that there have been times where we’ve inadvertently let our preconceived notions bleed into other aspects of our lives.” (MOUD provider, DO) |
| Interpersonal Barriers | |||
| Patients’ Interpersonal Barriers | Patient Quotes | Providers’ Interpersonal Barriers | Provider Quotes |
| Triggering social environments | “As for the actual NA [Narcotics Anonymous] groups, I haven’t done them lately…Sometimes they were helpful. Sometimes they weren’t. Cause, you know, sometimes you always have people that they’re not in the same mindset or they’re not ready [to stop opioid use]. And like, there are people there [at the NA meetings], that will be high. You’ll know that they’re high. And at that point in my life that was kind of a trigger for me when I would see other people high like that. Like, it would right away make me like, ‘Oh my god. I want to be like that.’” (Patient receiving naltrexone) | Social circle having stigmatized views of people with OUD | “My husband was worried about safety more than anything. Because I work in an office where the parking lot’s dark and sometimes I’m the last person to leave…And he was like, ‘If you’re prescribing opiates to people, aren’t they gonna--can that be dangerous?’ We got lights since then. It wasn’t really something I was super worried about with Suboxone. It’s not like I’m doing methadone prescribing, it’s just Suboxone.” (MOUD provider, DO) |
| Healthcare Setting Barriers | |||
| Patients’ Healthcare Setting Barriers | Patient Quotes | Providers’ Healthcare Setting Barriers | Provider Quotes |
| Time and frequency of appointments | “I would say the biggest annoyance with it is even though I’ve been regularly on Vivitrol [extended-release injectable naltrexone] now for how many months, after you get it, they still want you to sit there [in the primary care office during an MOUD appointment] for like 20 minutes just to make sure you don’t have a reaction. So, that’s kind of a pain because I know my boss understands and knows that I'm on it. She knows everything that happened in my past and everything like that. So, she wants me to stay clean and she wants to help. But at the same time, I think sometimes, like, when we’re really busy, I do think she gets a little annoyed about it…So, sometimes I just wish that I wouldn’t have to sit for that 20 minutes because it’s like I’ve been on this shot for how many months? And I do have a job and other requirements that I need to have taken care of.” (Patient receiving naltrexone) | Lack of MOUD providers in rural areas | “There are too many people [potential MOUD recipients] for the number of providers available. And there are not enough providers because no one wants to live in a rural area. And that’s just kind of the way it is.” (MOUD Provider, MD) |
| Lack of trust with provider and reluctance to discuss opioid use | “I mean, that’s an illegal activity [non-medical use of opioids]. It’s just something that you kept secret…It’s not like I wanted to rob the bank and show up and say, ‘Oh, yeah. I just robbed the bank.’ I mean, it’s an illegal activity. I just figured the less I admitted the better off I was.” (Patient receiving naltrexone) | Insufficient rapport with patients | “I think just that the overall stigma is still there. The patients are afraid to even talk about it. There’s always the denial, too. And the patients are afraid that they’ll get in trouble or get a record or lose their job or not be able to carry handguns or whatever some of these other issues are.” (MOUD Provider, MD) |
| Urine drug screens (UDS) | “It was the mistrust. Like, if they were to kick someone out of the program for other drug use because they test you…I’m saying if someone came up hot for marijuana and got booted off. A medication that helps them stay sober off of way worse substances. That’s why I didn’t really like the drug test. The potential to get kicked out of the program and a lot of people probably resort to criminal-like behavior, like faking their urines because of it.” (Patient receiving naltrexone) | Language Barrier | “We see more often than not some Hispanic patients, [who] just don’t speak English. It’s not been a personal problem where I ran into, but I want to preemptively—if we could get some resources in Spanish to hand out to patients who are having a problem [with addiction] and don’t speak English.” (MOUD Provider, PA) |
| Lack of time and office space | “They would have to be here for a few hours. We would have to administer the medication and then keep checking to see if they’re all right. That time of a patient being in there, when we have other patients who need to be getting in and out of their appointments. That means they’re taking up a room, or a couple of rooms that we need. So space would be an issue also. As it is now with our staff, we already feel kind of overwhelmed with other things.” (MOUD Provider, MD) | ||
| Staff turnover | “I feel like it’s time for another training [on providing MOUD in primary care]. Honestly, we just had two people leave our office, so we’re going to be hiring people soon hopefully. We’ll have a new team...we’re going to have a whole new staff in November.” (MOUD provider, MD) | ||
| Prior authorizations and reimbursement issues | “Prior authorization for the medication. Every insurance is different. Some like you to use pills, some like you to use tabs. When you’re trying to order the med, sometimes it gets denied. And then you’re fighting with the patient because the patient doesn’t understand you have to wait for the approval. I can order the med, but you’re not going to get it, or you’ll be paying out of pocket for it. And they just don’t understand that. So sometimes that can be a huge barrier, because now they’re going to lose trust in you as a provider because now you’re telling them they’re going to get the med and there’s a big hold up.” (MOUD provider, NP) | ||
| Lack of clear workflows | “When I got thrown into [providing MOUD], literally thrown into it, they were trying to teach all of the nurses how to give it. To learn more about it, so when we did get people, because we were getting our next [patient], and nobody knew how to do any of it because there was only one person that did it and she didn’t know what she was doing. The things that she did, she didn’t share with anyone else.” (RN) | ||
| COVID-19 mitigation efforts’ impact on care delivery | “The only barrier we have—the main one we have right now is Coronavirus. That has made things fun, not being able to see people in the office.” (MOUD Provider, MD) | ||
| Resistance from staff and administration | “We had faced some administrative struggles with getting started in MAT as far as our higher-ups, our administrators. In the way our hiring works, [they] didn’t want us to actually do that…Didn’t want us to be prescribing, to be doing Medication Assisted Treatment. They did not want us to…What I was told is, ‘Your partners don’t want those patients in their waiting room.’ That is what I was told.” (MOUD provider, MD) | ||
| Lack of behavioral health services in rural areas | “I think if maybe we had a behavioral health specialist or something to help with the patient’s behavioral issues. You know, because mental health and behavioral issues normally go hand in hand with substance abuse. And in our town, we really don’t have good behavioral health or mental health providers [nor] programs to really be able to refer them to.” (Practice manager in a RaMp clinic) | ||
| Poor communication between primary care and behavioral health | “So many times, with the integration of MAT when we’re dealing with outside referrals, the communication at times on our side and their side leaves a lot to be desired. It’s faxes instead of conversations. It’s a few words as opposed to a clinical report. It’s not being able to have the doctor come over and actually sit in a chair and say, ‘I just met with A, B, and C.’” (Counselor) | ||
| Community Barriers | |||
| Patients’ Community Barriers | Patient Quotes | Providers’ Community Barriers | Provider Quotes |
| Employment constraints | “I ended up quitting because the [boss] was too judgmental and knew my situation…It’s hard around here. Boy, it’s hard in a little town. Especially being a felon…It’s hard to even find a job or anything…I’ve tried god knows how many other places and they won’t hire me because my felonies haven’t been over seven years. So that makes you, right there, want to give up because who else is gonna hire you? Why not just go back to the criminal bullshit that you was doing?” (Patient receiving naltrexone) | Lack of awareness about MOUD services | “[County Drug and Alcohol] does have an agreement of some sort with the pharmacy, and they do provide us with vouchers, and they take care of the cost of the medication for the patient. A lot of patients don’t even know that exists until they get to that point. I think for people, in general, to be educated on ‘Hey, this program is out there. This is how it works. We’re here to help you.’ Those types of things [would be helpful].” (MOUD provider, PA) |
| Few or no places for sober socialization | “And the thing is, in my town, there is literally nothing for kids to do. Every place we have is basically closed down. We’ve had maybe two restaurants. We have more bars than anything. We used to have an arcade back when I was 12, and that’s where everybody used to go and hang out and spend their time. And if they could open up...just anything for kids to go to and stuff…I feel like it would help a lot of the circumstances going on in this area.” (Patient receiving buprenorphine) | ||
| Lack of community awareness about availability of MOUD | “[Opioid use] is pretty prevalent, like, everywhere. So, that was one of my things with getting the shot in [city] and my family doctor. I just didn’t know if they would do it or if they could do it because it’s like a small town. I didn’t know if they ever had anybody come in there and ask for it, or if it was popular at all.” (Patient receiving naltrexone) | ||
| Policy Barriers | |||
| Patients’ Policy Barriers | Patient Quotes | Providers’ Policy Barriers | Provider Quotes |
| Lack of transportation and long travel distances to MOUD provider | “It was really hard for me for a while to get back and forth to everything and constantly having to rely on rides everywhere...50 million phone calls to try and get everything straightened out…My drug and alcohol counseling is also in the same area that my PO’s [parole officer] office is. We don’t have buses that go out to that area…I would either have to walk from the shopping center to my house, which would probably take like 45 minutes or so…I guess I could take a taxi because I know they do have taxi services, but I just always thought that would probably be really expensive. And like, when I first got out [of prison] and everything, money was kind of tight for me.” (Patient receiving naltrexone) | Certification process of obtaining DATA 2000 Waiver | “I think the biggest barrier was, essentially, me getting the certification…So I went ahead, I got my certification, my DATA 2000 Waiver, and then started my agreement…For the first couple of years, I’m limited to how many patients I’m actually allowed to treat. The worst part of getting my certification was getting my new DEA registration card. I could not get a hold of the DEA to save my life and I had met all the criteria.” (MOUD provider, PA) |
| Cost of care | “My boyfriend, he used to be on [naltrexone], but he’s somebody that lost his medical assistance when he got his job because he makes too much money now. So, he had to stop Vivitrol. He says all the time how he wishes that he could have stayed on it because it just made him feel more secure and everything.” (Patient receiving naltrexone) | Limits placed on the number of MOUD patients | “I believe with my DATA 2000 Waiver, for the first couple of years, I’m limited to how many patients I’m actually allowed to treat.” (MOUD Provider, PA) |
Table 2:
Representative quotes of facilitators for receiving and providing MOUD
| Individuals’ Facilitators | |||
|---|---|---|---|
| Patients’ Individual Facilitators | Patient Quotes | Providers’ Individual Facilitators | Provider Quotes |
| Receiving preferred type of MOUD | “The reason that Vivitrol helped was because of the way that the medicine works. If you’re on another medicine, you can still use heroin or any other opiate. It doesn’t keep you from using anything. If you’re on Suboxone, first of all, it still kind of gets you high. Second of all, if you use it in a certain way, you can still use opiates…With the Vivitrol, as long as you go get your shot, you’re not going to get high. It doesn’t matter because your receptors are blocked…It makes you learn how to deal with your problems without getting high.” (Patient not currently receiving MOUD, but who was previously prescribed naltrexone, methadone, and buprenorphine) | Inclination, knowledge, and skills to provide MOUD | “I saw it as a big need that people need help for, specifically in our area. In Pennsylvania, there’s a lot of patients who do use opioids. And there really wasn’t that many providers in the area…In medical school, I worked in a methadone clinic for a little while…So, I’ve always had that interest. I’d always kind of known I wanted to get my Waiver to prescribe to help people.” (MOUD provider, MD) |
| Understanding addiction as a chronic disease | “We’re just like everybody else, but we have an addiction. Which is a disease! Just like other diseases, that’s what they say.” (Patient receiving buprenorphine) | ||
| Interpersonal Facilitators | |||
| Patients’ Interpersonal Facilitators | Patient Quotes | Providers’ Interpersonal Facilitators | Provider Quotes |
| Adequate social support and accountability | “I feel like the people that I’m getting the most support from are my friends, my family, for sure. My family has always made sure I’ve had rides to my appointments, before I got my car, to my doctor’s appointments, to work. Everything. To see my PO [parole officer]. I live quite a bit away from my PO’s office. So, you know, my parents, they’d have to drive a little bit out of their way just to make sure that I would get there and everything. But they’ve all been very supportive. And I’ve had a lot of people that I’m friends with that have told me how proud they are of me and everything like that.” (Patient receiving naltrexone) | Sharing success stories with other providers | “I think that a lot of it comes naturally just as...[providers have] seen success with some of our patients. I think that really started with Vivitrol. I think initially some of the people were a little bit nervous about working with addiction, but as they saw [the patients] and saw their success, I think it was like, ‘Oh! This is great, this is exciting!’ This person is now working at the deli, or this person has it together and is working as a counselor. I think that being able to see them succeed has really helped with some of the stigma.” (MOUD provider, MD) |
| Healthcare Setting Facilitators | |||
| Healthcare Setting Facilitators | Patient Quotes | Healthcare Setting Facilitators | Provider Quotes |
| Good therapeutic partnership and shared decision-making with MOUD provider | “My doctor up here, they’re just a lot more involved. They actually care and they want to see you more often and they want to talk to you about things…Just for them to interact with me and ask me about my life and how’s everything going and just show they genuinely care.” (Patient receiving naltrexone) | A trusting therapeutic relationship with patients | “Talk to them. I mean, it’s the best thing to do. Just be real and talk to them…The answer is you gotta care about the patient. That’s the only answer I can give you. Because we care about the person. And you do! You don’t get short. You don’t walk out. You don’t give up. You got to make a choice to care about them…As long as you have the right heart and they’re important, you can do something with them. Patients will see through that right away, if you don’t care.” (MOUD provider, DO) |
| Flexibility in (re-) scheduling | “And there has been a time when my work schedule would have conflicted with my [MOUD] appointment, and they actually called another patient and asked if they could bump him to a different time slot to bump me in a little earlier so that I could make it and get my injection before I had to go to work…They’re pretty good about trying to work with me.” (Patient receiving naltrexone) | Whole-person and longitudinal care | “Our vision is to take care of [addiction] as a family doctor, or as a primary care clinician, or provider. So that we are treating, we are managing you with your Substance Use Disorder as well as your neuropathy as well as your depression, or what have you. So, that’s really where I see the role of primary care fitting in. Maintenance in the context of providing whole person primary care over the course of time. Longitudinal care.” (MOUD provider, MD) |
| Well-coordinated care | “All of my [counselors] are very helpful, nice. And they listened to me and they help me, like if I need transportation. Things like that.” (Patient receiving buprenorphine) | Detailed protocols and workflows for providing MOUD | “You need office support to do this…What really makes a difference to whether or not this is going to work is how does it function? The nuts and bolts. Who is going to be doing what? How much time do they need? Real, practical information. What are the barriers to get these drugs [MOUD]? The information on prior authorization. How do the drugs [MOUD] need to be kept? Where does it need to be kept?” (MOUD provider, MD) |
| Accessible materials for patients about MOUD to facilitate discussions | “When our patients that aren’t part of the [RAMP] program are sitting out there, they have something to read at their convenience that we are not hounding them about. But then to let them feel maybe they want to bring it up to us when they do get into the room.” (MOUD provider, PA) | ||
| Partnerships with Single County Authorities (SCA), Emergency Departments (ED), and Emergency Medical Services (EMS) to establish patient referrals to primary care for MOUD | “The RAMP people went to meetings with me. They came down to the County Drug and Alcohol and met with them with me. We went to the [rehabilitation facility] and met with them together…I told them exactly what I wanted and how I wanted it set up. And then they got me in touch with the right people and came to the meetings with me. Once we had it all set up to where I felt comfortable, we had more of a support system than us just prescribing Suboxone. We started the referral process and bringing patients in.” (Practice manager in a RAMP clinic) | ||
| Community Facilitators | |||
| Community Facilitators | Patient Quotes | Community Facilitators | Provider Quotes |
| Wraparound services to meet basic needs | “The lady I was telling you about...would give me her number. She asks how everything’s going, if anything’s bothering me, what can she do to help, this or that. My case management does the same thing. Like, ‘Hey, do you need any clothes? What about money, like rent? Everything going good?’” (Patient receiving naltrexone) | Partnering with local organizations | “We’ve worked with grassroots partners. We have some partnerships with local mechanics and if they’re doing a recovery event, they’ll provide transportation. But we’re also working with Lyft. So, our health network has a contract with Lyft so that we can provide Lyft services for those that have identified needs.” (Community-based rural health network director) |
| Overcoming a “bad reputation” in a small, rural town | “The nurses are really nice. They’re about their job and their clients. I’m from a small town and I know quite a bit of people. I got a reputation, like a bad reputation. And they treat me with respect. They don’t give a shit what I was doing before. I’m just there to get treated for opiate abuse and they’re always happy-go-lucky and real considerate with me.” (Patient receiving naltrexone) | Establishing a common language for multidisciplinary collaboration | “Addiction just comes with acronym soup that feels ridiculous. Maybe not quite as much as mental health. I feel like I stepped in the room with mental health practitioners and I’m even more lost. But the Substance Use Disorder field just alienates people....we were all thinking we were collaborating, but there actually wasn’t that critical thinking going on that leads to shared understanding or common vision for what should be happening.” (Development officer) |
| Informational materials about MOUD services | “More advertising would be nice. Because a lot of people don’t know about [MoUd]. If they happen to sit here and say, ‘I’m drinking a 12-pack a night now.’ Or, ‘I’m having trouble getting off these pain pills.’ If they don’t say stuff like that, we don’t know. We could say, ‘Okay, we have this to offer you.’ If they see something like that, they might say, ‘I could benefit from that.’” (RN) | ||
| Policy Facilitators | |||
| Patients’ Policy Facilitators | Patient Quotes | Providers’ Policy Facilitators | Provider Quotes |
| Policies aimed at easing reintegration into the community after incarceration or rehabilitation | “I can speak from experience because your first year out of jail is crazy, trying to get re-acclimated. When you’re in jail, they serve you your meals, they do your laundry. And then, you get out and you have to make all these decisions for yourself that you didn’t have to before because you kind of sat in there like a slug and you have no control. They have all the control. So, for 10 and a half months, I made no decisions for myself because I didn’t have control of my decisions. So, to go from that to come out and have to make all your decisions again, do all your work again, and try to find a job on top of that, especially if you’re a felon, that’s stressful.” (Patient not currently receiving MOUD, but who was previously prescribed naltrexone, methadone, and buprenorphine) | Resources and support while obtaining DATA 2000 Waiver | “For physicians, they need eight hours, but for mid-levels they need 24 hours, which is obviously the barrier for a lot of people…I think congressionally we’re talking about making it easier by doing away with all of this extra Waivering process…There have been bills that have been introduced that try to do that.” (Development officer) |
| Medical insurance coverage with low or no co-pays | “My insurance company, they’re supportive of [MOUD]. And, yeah. Every time I go in and get my script, I only have to pay like one dollar.” (Patient receiving buprenorphine) | ||
3.1. Barriers to OUD Treatment in Rural Primary Care
The barriers to providing and receiving MOUD in rural primary care settings are organized by social ecological level (Figure 1).
Figure 1.

Barriers to providing and receiving MOUD care in rural primary care settings organized by social ecological level
3.1.1. Individuals’ Barriers
For people with OUD, stigma pervades their lives at internal, interpersonal, and wider levels. Patients reported that ambivalence towards ceasing opioid use and felt stigma were barriers to seeking treatment at the individual level. In addition, patients themselves held stigmatized views about MOUD options. For instance, six patients shared their opinions that naltrexone was better than buprenorphine and methadone, which some viewed as “substituting one substance for another.” This sentiment demonstrates stigmatized views against specific types of MOUD, which may affect uptake of treatment options.
In considering the barriers they faced at an individual level, providers cited their lack of formal training in addiction treatment and reluctance to perform MOUD inductions. Providers acknowledged that unrecognized stigma among colleagues may be a potential barrier. In addition, some providers expressed views that demonstrated they were not conscious of their biases about people with OUD.
3.1.2. Interpersonal Barriers
Interpersonal barriers for patients included social environments in which they were tempted to use opioids and having a social circle that did not understand the nature of addiction or how MOUD could be part of a treatment regimen.
Speaking about their own social circles, some providers discussed the role of their family members’ opinions about people with OUD and how this translated into concerns about work safety. Similar to patients’ preferences about MOUD type, the providers noted that the type of MOUD they provided in primary care settings was important in gaining confidence of their family members, with one provider stating that “it’s not like I’m doing methadone prescribing.”
3.1.3. Healthcare Setting Barriers
In this modified social ecological framework, we have added a category to the traditional social ecological framework: the healthcare setting. At this level, themes pertain to interpersonal interactions with healthcare professionals, operations in the primary care setting, as well as coordination of care with other services relevant for OUD treatment. Patients identified multiple barriers: time and frequency of appointments, lack of trust with their provider and a reluctance to discuss opioid use, and burdensome urine drug screens (UDS).
The healthcare setting level barriers for providers were extensive. Providers noted that the existence of few MOUD providers in rural areas potentially translated into more patient need for MOUD than was able to be addressed, insufficient rapport with patients, language barriers, lack of time and office space, staff turnover, issues with prior authorization and reimbursement, lack of clear workflows, Covid-19 mitigation efforts’ impact on care delivery, resistance from staff and administration, lack of behavioral health services, and poor communication between primary care and behavioral health.
3.1.4. Community Barriers
Patients highlighted inflexibility of one’s job and work schedule, few or no places for sober socialization, and lack of community awareness about availability of MOUD.
At the community level, providers also reported that there was a lack of awareness about the MOUD services they offer. Some providers noted that their practice’s administrators did not want them to advertise their MOUD services.
3.1.5. Policy Barriers
In the public policy realm, patients described barriers regarding the lack of public transportation and long travel distances to MOUD providers, and the high cost of health care.
Providers described the certification process of obtaining a DATA 2000 Waiver as burdensome. For nurse practitioners and physician assistants, the burden was higher because more hours were required to complete their training. In addition, although no providers in our study reached their patient limit, they noted the possibility of not being able to provide MOUD to all patients who might need it should demand increase.
3.2. Facilitators to OUD Treatment in Rural Primary Care
In addition to discussing the barriers to MOUD in rural primary care settings, patients and providers discussed supportive factors, or facilitators. These are displayed in Figure 2.
Figure 2.

Faciliators to providing and receiving MOUD care in rural primary care settings organized by social ecological level
3.2.1. Individuals’ Facilitators
Patients said that having their preference honored for the type of MOUD they received was a facilitator. Of the interviewed patients, seven received naltrexone and two were prescribed buprenorphine. Most of the patients interviewed shared their opinions that naltrexone (a long-acting injection they receive once monthly) served them better than other types of MOUD. Patients also noted that developing their own understanding of addiction as a lifelong, chronic disease were facilitators at the individual level.
Providers said that having the inclination, knowledge, and skills to provide MOUD were facilitators for them. Providers identified a variety of factors that motivated them to provide MOUD from wanting to increase access to MOUD in rural areas to pursuing professional development in addiction medicine. Some providers shared that a personal experience with addiction or knowing someone with substance use disorder (SUD) propelled them into providing MOUD.
3.2.2. Interpersonal Facilitators
Interpersonal facilitators such as having sources of accountability and social support were critical, according to patients.
Providers said their interpersonal relationships with colleagues was a facilitator. Sharing success stories about people receiving MOUD helped to allay reservations about providing MOUD.
3.2.3. Healthcare Setting Facilitators
Patients appreciated feeling “like a regular patient” when going to primary care clinics for MOUD. Having providers who “genuinely care” was repeated by multiple patients as a valuable asset in treatment. Flexibility in (re-)scheduling appointments was one of the most important facilitators for patients. As patients described in interviews, people in OUD treatment programs often have multiple activities they must attend for their recovery--meetings with drug and alcohol counselors, narcotics anonymous (NA) meetings, and MOUD appointments--and they have to balance these with other obligations, such as work and childcare. In some cases, patients reported how missed appointments with clinics that were not flexible with rescheduling led to disruption in treatment. Well-coordinated care between MOUD provide and behavioral health services was also a facilitator for patients.
Providers suggested multiple healthcare setting specific facilitators for easing MOUD provision in their primary care practices. Mirroring what patients said, providers noted that cultivating a trusting therapeutic relationship with patients was key in providing MOUD. The setting of primary care was conducive for MOUD provision because it emphasizes whole-person care and leverages longitudinal relationships with patients. Developing and instituting detailed protocols and workflows for providing MOUD was a facilitator. Accessible materials for patients in waiting rooms, in both English and Spanish, helped to facilitate discussions about addiction and treatment options with patients. Providers stated that partnerships with Single County Authorities (SCA), Emergency Departments (ED), and Emergency Medical Services (EMS)—partnerships facilitated by Project RAMP--were instrumental for establishing patient referrals for treatment.
3.2.4. Community Facilitators
Patients reported that their treatment for OUD was profoundly shaped by whether or not their basic needs were met. Specifically, patients discussed how having sufficient food, shelter, and transportation were all essential for one’s stability in recovery. In this way, wraparound services were a critical facilitator for patients. For some patients, it was important to overcome their “bad reputation” and gain trust with service providers and community members while living in a small, rural town.
Partnering with local organizations that serve people with OUD was a facilitating factor at the community level, providers stated. Establishing a common language for multidisciplinary collaboration with these community organization partners, providers noted, was also an important facilitator. Providers said that disseminating informational materials about MOUD services into the community would be a facilitating factor because more potential MOUD patients and people in their social circles would learn more about treatment options for MOUD.
3.2.5. Policy Facilitators
For patients, policies aimed at easing reintegration into the community after incarceration or inpatient rehabilitation were important facilitators. All patients who were interviewed, by design, were Medicaid recipients, and they reflected that having medical insurance coverage with low or no co-pays was critically important for their access to MOUD.
Some providers suggested that changing the DATA 2000 Waiver policy would increase patient access to MOUD. Policy shifts are currently underway at the national level to no longer require any DATA 2000 Waiver training for providers who wish to prescribe MOUD.
4.0. Discussion
This study examined patient and provider experiences with MOUD in rural primary care settings, focusing on both barriers and facilitators. By organizing the findings into tiers of a modified social ecological framework at the individual, interpersonal, healthcare setting, community, and policy levels, we were able to gain an understanding of where patients’ and providers’ experiences with MOUD intersect and diverge. Our findings differ in that many studies do not discuss implementation-focused questions, and thus our summary of provider-identified facilitators in operationalizing MOUD in their primary care clinic in a rural setting is novel.
A clear pattern emerged: patients described their experiences in broad terms, highlighting their lives outside of the therapeutic encounter in the clinic, experiences which may be outside the purview of providers. Providers, on the other hand, focused on their professional roles, responsibilities, and operations within the primary care setting. Because social determinants of health affect health outcomes and quality of life, understanding how systems differentially impinge upon patients’ treatment experiences is valuable to clinicians and policy-makers.
When viewed separately, our findings on provider and patient perspectives on barriers and facilitators in receiving MOUD are consistent and build upon other published studies. A recent review of the literature by Hall et al. (2021) on patient-identified barriers found that negative perceptions towards MOUD (e.g., substituting one drug for another), cost, stigma, lack of flexibility in treatment, and access issues (e.g., lack of prescribers) were the most frequently identified themes across studies. Social barriers, such as employment and peers using illegal substances, were also cited and mirror some of our findings. Regarding providers, a timely systematic review of qualitative studies focused on MOUD treatment found themes of stigma towards patients with OUD, which were rooted in a lack of training in addiction treatment and preference towards abstinence-based treatment (Madden et al., 2021).
There are some study limitations of note. The experiences this study captured from patients and providers in rural communities in Pennsylvania may not be transferable to all rural areas in Pennsylvania or across the United States. Patients and providers who participated in the interviews may not have come from the same clinic environments. There were notable challenges to recruiting patients resulting in a smaller sample than we initially hoped for. The study team did not directly recruit patients; instead the study team disseminated recruitment packets to providers who then gave them to patients. Utilizing packets distributed by providers was the best option available, as our budget did not allow us for placing study personnel within clinics. With only nine interviews conducted with patients, thematic saturation may not have been reached and thus there may have been additional experiences that were not captured. Because all interviewed patients were Medicaid beneficiaries, the interview data does not necessarily reflect the experiences of people without health insurance or with other types of health insurance. Seven of the nine patients interviewed for this study used naltrexone, which departs from the national trend of more MOUD patients receiving buprenorphine than naltrexone (MODRN et al., 2021).
The results of this study have the potential to inform policies seeking to improve the provision and receipt of MOUD. Recruiting more MOUD providers and behavioral health services, as well as increasing higher MOUD patient caseloads, would enhance healthcare delivery in rural settings. Under section 1262 of the Consolidated Appropriations Act of 2023, the DATA 2000 Waiver is no longer a federal requirement, and the related patient limits have been removed (SAMHSA 2023). These updated requirements for the DATA 2000 Waiver may help rural areas with high rates of OUD. Further, interviewees underscored the importance of formulating detailed prescribing guides and MOUD protocols for rural providers and staff. Collaboration and referrals among primary care, behavioral health services, and local human services agencies could be improved by creating clear and uniform standards for primary care to collaborate with these entities. Because transportation and childcare are significant barriers facing patients, providers may consider partnering with agencies that provide these services to enhance patient experience and facilitate treatment engagement. Educating patients, their families, and communities about the chronic disease of addiction can be useful in dispelling myths regarding MOUD. Interviewees suggested that outward-facing materials to combat stigma about addiction and MOUD would be useful for audiences of their choosing, such as housing programs and employers. Raising awareness through anti-stigma campaigns may be useful for the broader community. Such efforts have been tested in rural Colorado (The Regents of the University of Colorado, 2022). Another way to positively impact the broader community in rural areas would be to establish more places for sober socializing.
5.0. Conclusion
Using a qualitative approach, this study examined both the barriers and facilitators patients and providers experienced regarding MOUD in rural primary care settings. The modified social ecological framework allowed us to be attentive to OUD management at multiple levels (individual, interpersonal, healthcare setting, community, and public policy). Future efforts to improve care delivery for patients with OUD may build alliances among providers and patients to address shared systemic barriers as well as to advance awareness of barriers particular to either group. The findings from these interviews point to potential opportunities to enhance patient experience, increase access to and optimize processes for MOUD in rural areas, and reduce stigma in the wider community.
Acknowledgments
We would like to express our gratitude to all of the patients and providers who participated in this project, dedicating their time and sharing their experiences with us.
Funding
This study was supported by a grant from the Agency for Healthcare Research and Quality [5R18HS025072, PI: DiDomenico].
List of Acronyms
- AHRQ
Agency for Healthcare Research and Quality
- BH
Behavioral health
- COE
Center of Excellence
- DO
Doctor of Osteopathic Medicine
- DATA 2000
Drug Addiction Treatment Act of 2000
- ED
Emergency Department
- EMS
Emergency Medical Services
- MAT
Medication-assisted treatment
- MD
Medical Doctor
- MOUD
Medications for opioid use disorder
- NA
Narcotics Anonymous
- OBOT
Office based opioid treatment
- OTP
Opioid treatment programs
- OUD
Opioid use disorder
- PA
Physician assistant
- PCP
Primary care providers
- PO
Parole officer
- RAMP
Rural Access to Medication-Assisted Treatment in Pennsylvania
- SBIRT
Screening, brief intervention, and referral to treatment
- SCA
Single County Authority
- SUD
Substance use disorder
- UDS
Urine drug screens
Appendix A: RAMP Provider Qualitative Interview Guide
Thank you for participating in this brief interview about your participation and experience with the Project RAMP (Rural Access to MAT in Pennsylvania) intervention. The information you provide today will help the Project RAMP research and implementation teams evaluate the processes and components of the project and provide insights into the degree to which and how the project assisted your clinic in the adoption of MAT practices, such as prescribing buprenorphine and/or naltrexone, conducting screening, brief intervention, and referral to treatment (SBIRT), and linking patients with care management.
We will record the interview so that we can capture an accurate account of today’s conversation. Once the recording is transcribed, we will redact any identifying information from the transcript, and the audio file of today’s conversation will be destroyed. To the extent possible, the information you provide will be deidentified. Again, the purpose of this interview is to better understand the experiences of RAMP participants, so we can inform future initiatives that seek to facilitate MAT adoption in rural primary care settings.
Do you have any questions or concerns before we begin?
Stakeholder’s role (choose one for each interviewee) (Physician, Champion, Other Staff)
(Note how many interviewees are participating in the interview)
-
Please tell me how and when you became involved in Project RAMP.
How would you describe the recruitment process?
What concerns or hesitancies, if any, did you or others (partners or staff) have about participation?
-
To what extent did you have input into your level of participation in RAMP?
How were your preferences incorporated into the process of providing MAT services?
What were your main reasons for participating in RAMP?
-
Prior to participating in RAMP, what barriers, if any, did you believe would affect your ability to provide MAT?
-
(If they describe any barriers) How do you view those barriers now?
Were these barriers more or less difficult to overcome than you initially thought? How so?
How were those barriers overcome?
Which barriers persist?
-
-
Bringing a provider into Project RAMP usually involves a number of activities including a site visit from the implementation team, presentations on MAT and SBIRT, a self-evaluation of organizational health (questionnaire), and sometimes the mapping of the office workflow and space. Please tell me about what aspects of this “onboarding process” you felt were most helpful or useful, and why.
Please tell me about what aspects of the onboarding process you felt were less helpful, unnecessary, or could be improved.
What, if anything, would you change about the recruiting and “onboarding” process?
-
Once a provider is an active participant in Project RAMP, a number of activities are conducted based on the provider’s needs including weekly calls with the provider, trainings in motivational interviewing, stigma reduction, role playing, online trainings, progress reports and feedback, data collection/reporting, and “lunch and learns.” Which activities did you participate in?
Which of these activities were most helpful, and why?
Which were the least helpful and why?
Were there other activities not listed here that were helpful? If so, why?
-
Project RAMP aims to connect providers with Care Management teams, Centers of Excellence (COEs) and/or Single County Authorities. Did Project RAMP provide connections for you and, if so, how would you describe that process?
What challenges, if any, were there with connecting and working with care managers?
In what ways did connecting with care management help you adopt MAT practices?
Can you describe any issues, problems, or concerns about your Project RAMP participation?
-
What recommendations, if any, do you have for improving or enhancing Project RAMP?
More generally, what are 2–3 things you believe would increase your ability to provide MAT?
Considering everything we talked about today, what is your outlook on your ability to continue providing MAT into the future?
Appendix B: MOUD Patient Interview Guide
Patient satisfaction
-
Overall tell me how you think your medication assisted treatment with buprenorphine (e.g., Suboxone, Zubsolv, Subutex) or naltrexone (e.g., Vivitrol, Revia) is going.
Tell me about how this prescription medication helped you.
Tell me about how this medication has not helped you.
Tell me about the support (or lack of support) you have received in using these medications.
What problems, if any, have you had in taking this medication?
-
Who else has been involved in your treatment for opioid use? This could include mental health providers, peer navigators, or case manager.
Tell me about how they have been a support or not with regards to your opioid use disorder treatment.
What problems, if any, have you had accessing or using mental health or case manager support?
What not so good things have come from accessing or using mental health providers or case manager supports?
What positives or good things have come from your accessing or using mental health or case manager support?
Tell me about your progress (or lack of progress) with your treatment from mental health providers.
-
Thinking now just about your primary care provider (i.e., the PCP who prescribes your medication for your opioid use disorder), tell me about your experience getting treatment for your opioid use disorder from this provider.
How has treatment changed over time?
How does your treatment at this PCP compare to the treatment you’ve received at other providers?
Tell me about any problems communicating with your PCP (including staff).
Describe how you feel you are treated by this PCP (including staff).
-
Have you received help for your opioid use in a mutual support group such as Alcoholics Anonymous or Narcotics Anonymous? (If so) Tell me about your progress (or lack of progress) with your mutual support groups.
Tell me about the support (or lack of support) you have received in using these programs.
What barriers or issues, if any, have you had to accessing or participating in drug and alcohol mutual support groups?
Tell me about how mutual-support groups you attended felt about individuals on medication-assisted treatment with buprenorphine or naltrexone.
How did this influence your experience with the mutual-support group?
What positives or good things have come from your accessing or participating in drug and alcohol mutual support groups?
Access
-
Tell me about any issues or concerns you’ve had with scheduling or getting to appointments with any of the providers we just talked about.
Any issues with travel distance, transportation, child care?
Any issues with frequency of visits?
Any issues with medical insurance coverage related to any aspects of your opioid use disorder treatment?
Continuity of care/care coordination
(If reports seeing a case manager in question 2) Tell me about how well or poorly you think your PCP communicates with your case manager about your opioid use disorder.
Summary
What is the most important thing that can make your drug treatment with buprenorphine (e.g., Suboxone, Zubsolv, Subutex) or naltrexone (e.g., Vivitrol, Revia) (with your physician, their staff, care manager, drug treatment provider, mental health provider) successful?
What could your [physician, their staff, care manager, drug treatment provider, mental health provider] do to help you in your treatment?
The RAMP program is designed to expand access to treatment for opioid use disorder by assisting PCPs in rural areas to adopt practices to treat addiction. What do you think are the best ways to expand access to treatment for opioid use disorder?
Footnotes
Competing Interests
The authors declare that they have no competing interests.
The project was originally named when MAT was the broadly used term, which has since been updated to Medications for Opioid Use Disorder (MOUD).
References
- Andraka-Christou B, & Capone MJ (2018). A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. International Journal of Drug Policy, 54, 9–17. 10.1016/j.drugpo.2017.11.021 [DOI] [PubMed] [Google Scholar]
- Andrilla CH, A., Moore TE, & Patterson DG (2019). Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: Recommendations from rural physicians. The Journal of Rural Health, 35(1), 113–121. 10.1111/jrh.12328 [DOI] [PubMed] [Google Scholar]
- Baron SL, Beard S, Davis LK, Delp L, Forst L, Kidd-Taylor A, Liebman AK, Linnan L, Punnett L, & Welch LS (2014). Promoting integrated approaches to reducing health inequities among low-income workers: Applying a social ecological framework. American Journal of Industrial Medicine, 57(5), 539–556. 10.1002/ajim.22174 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barry DT, Irwin KS, Jones ES, Becker WC, Tetrault JM, Sullivan LE, Hansen H, O’Connor PG, Schottenfeld RS, & Fiellin DA (2009). Integrating buprenorphine treatment into office-based practice: A qualitative study. Journal of General Internal Medicine, 24(2), 218–225. 10.1007/s11606-008-0881-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bernard HR (2017). Research methods in anthropology: Qualitative and quantitative approaches (6th ed.). Rowman & Littlefield Publishers. https://rowman.com/ISBN/9781442268883/Research-Methods-in-Anthropology-Qualitative-and-Quantitative-Approaches-Sixth-Edition [Google Scholar]
- Braun V, & Clarke V (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77–101. 10.1191/1478088706qp063oa [DOI] [Google Scholar]
- Browne T, Priester MA, Clone S, Iachini A, DeHart D, & Hock R. (2016). Barriers and facilitators to substance use treatment in the rural south: A qualitative study. The Journal of Rural Health, 32(1), 92–101. 10.1111/jrh.12129 [DOI] [PubMed] [Google Scholar]
- Bunting AM, Oser CB, Staton M, Eddens KS, & Knudsen H (2018). Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: A socio-ecological approach. Addiction Science & Clinical Practice, 13(1), 13–23. 10.1186/s13722-018-0124-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chapman AL, Hadfield M, & Chapman CJ (2015). Qualitative research in healthcare: An introduction to grounded theory using thematic analysis. The Journal of the Royal College of Physicians of Edinburgh, 45(3), 201–205. 10.4997/JRCPE.2015.305 [DOI] [PubMed] [Google Scholar]
- Cochran G, Cole ES, Warwick J, Donahue JM, Gordon AJ, Gellad WF, Bear T, Kelley D, DiDomenico E, & Pringle J (2019). Rural access to MAT in Pennsylvania (RAMP): A hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers. Addiction Science & Clinical Practice, 14, 25. 10.1186/s13722-019-0154-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cole ES, DiDomenico E, Cochran G, Gordon AJ, Gellad WF, Pringle J, Warwick J, Chang CH, Kim JY, Kmiec J, Kelley D, & Donahue JM (2019). The role of primary care in improving access to medication-assisted treatment for rural Medicaid enrollees with opioid use disorder. Journal of General Internal Medicine, 34(6), 936–943. 10.1007/s11606-019-04943-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cole ES, DiDomenico E, Green S, Heil SKR, Hilliard T, Mossburgh SE, Sussman AL, Warwick J, Westfall JM, Zittleman L, & Salvador JG (2021). The who, the what, and the how: A description of strategies and lessons learned to expand access to medications for opioid use disorder in rural America. Substance Abuse, 42(2), 123–129. 10.1080/08897077.2021.1891492 [DOI] [PubMed] [Google Scholar]
- Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mharte-Owens A, Dungan MT, & Hagedorn H (2020). Stepped care for opioid use disorder train the trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Substance Abuse, 41(3), 275–282. 10.1080/08897077.2020.1787299 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hall NY, Le L, Majmudar I, & Mihalopoulos C (2021). Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. Drug and Alcohol Dependence, 221. 10.1016/j.drugalcdep.2021.108651 [DOI] [PubMed] [Google Scholar]
- Hutchinson E, Catlin M, Andrilla CHA, Baldwin L, & Rosenblatt RA (2014). Barriers to primary care physicians prescribing buprenorphine. The Annals of Family Medicine, 12(2), 128–133. 10.1370/afm.1595 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Joudrey PJ, Edelman EJ, & Wang EA (2019). Drive times to opioid treatment programs in urban and rural counties in 5 US states. Journal of American Medical Association, 322(13), 1310–1312. 10.1001/jama.2019.12562 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Joudrey PJ, Bart G, Brooner RK, Brown L, Dickson-Gomez J, Gordon A, Kawasaki SS, Liebschultz JM, Nunes E, McCarty D, Schwartz RP, Szapocnik J, Trivedi M, Tsui JI, Williams A, Wu L, & Fiellin DA (2021). Research priorities for expanding access to methadone treatment for opioid use disorder in the US: A National Institute on Drug Abuse Center for Clinical Trials Network task force report. Substance Abuse, 42(3), 245–254. 10.1080/08897077.2021.1975344 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Joudrey PJ, & Gordon AJ (2021, December 22). Inflexible methadone regulations impede America’s efforts to reduce overdose deaths. STATnews. https://www.statnews.com/2021/12/22/inflexible-methadone-regulations-impede-efforts-reduce-overdose-deaths/ [Google Scholar]
- LaBelle CT, Han SC, Bergeron A, & Samet JH (2016). Office-based opioid treatment with buprenorphine (OBOT-B): Statewide implementation of the Massachusetts Collaborative Care Model in community health centers. Journal of Substance Abuse Treatment, 60, 6–13. 10.1016/j.jsat.2015.06.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lister JJ, Weaver A, Ellis JD, Himle JA, & Ledgerwood DM (2020). A systematic review of rural-specific barriers to medicaiton treatment for opioid use disorder in the United States. The American Journal of Drug and Alcohol Abuse, 46(3): 273–288. 10.1080/00952990.2019.1694536 [DOI] [PubMed] [Google Scholar]
- Mackey K, Veazie S, Anderson J, Bourne D, & Peterson K (2019). Evidence brief: Barriers and facilitators to use of medications for opioid use disorder. Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009. [PubMed] [Google Scholar]
- Madden EF, Prevedel S, Light T, & Sulzer SH (2021). Intervention stigma toward medications for opioid use disorder: A systematic review. Substance Use & Misuse, 56(14), 2181–2201. 10.1080/10826084.2021.1975749 [DOI] [PubMed] [Google Scholar]
- McLeroy KR, Bibeau D, Steckler A, & Glanz K (1988). An ecological perspective on health promotion programs. Health Education Quarterly, 15(4), 351–377. 10.1177/109019818801500401 [DOI] [PubMed] [Google Scholar]
- The Medicaid Outcomes Distributed Research Network (MODRN), Donohue JM, Jarlenski MP, Kim JY, Tang L, Ahrens K, Allen L, Austin A, Barnes AJ, Burns M, Chang CH, Clark S, Cole E, Crane D, Cunningham P, Idala D, Junker S, Lanier P, Mauk R, McDuffie MJ, Mohamoud S, Pauly N, Sheets L, Talbert J, Zivin K, Gordon AJ, & Kennedy S (2021). Use of medications for treatment of opioid use disorder among U.S. Medicaid enrollees in 11 states, 2014–2018. Journal American Medical Association, 326(2), 154–164. 10.1001/jama.2021.7374 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Molfenter T, Fitzgerald M, Jacobson N, McCarty D, Quanbeck A, & Zehner M (2019). Barriers to buprenorphine expansion in Ohio: A time-elapsed qualitative study. Journal of Psychoactive Drugs, 51(3), 272–279. 10.1080/02791072.2019.1566583 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nourjah P, & Kato E (2021). “One size does not fit all” and other lessons learned from grants for implementation of the AHRQ medication assisted treatment for opioid use disorder in rural primary care. Substance Abuse, 42(2), 136–139. 10.1080/08897077.2021.1891600 [DOI] [PubMed] [Google Scholar]
- Oros SM, Christon LM, Barth KS, Berini CR, Padgett BL, & Diaz VA (2021). Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina. The International Journal of Psychiatry Medicine, 56(1), 14–39. 10.1177/0091217420946240 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Perry C, Liberto J, Milliken C, Burden J, Hagedorn H, Atkinson T, McKay JR, Mooney L, Sall J, Sasson C, Saxon A, Spevak C, Gordon A, & VA/DoD Guideline Development Group. (2022). The management of substance use disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Annals of Internal Medicine, 175(5), 720–731. 10.7326/M21-4011 [DOI] [PubMed] [Google Scholar]
- The Regents of the University of Colorado. (2022). IT MATTTRS. https://medschool.cuanschutz.edu/itmatttrs/community-awareness-materials [Google Scholar]
- Saunders EC, Moore SK, Gardner T, Farkas S, Marsch LA, McLeman B, Meier A, Nesin N, Rotrosen J, Walsh O, & McNeely J (2019). Screening for substance use in rural primary care: A qualitative study of providers and patients. Journal of General Internal Medicine, 34(12), 2824–2832. 10.1007/s11606-019-05232-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saunders EC, Moore SK, Walsh O, Metcalf SA, Budney AJ, Scherer E, & Marsch LA (2020). Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. Journal of Substance Abuse Treatment, 111, 54–66. 10.1016/j.jsat.2020.01.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Snell-Rood C, Pollini RA, & Willging C (2021). Barriers to integrated medication-assisted treatment for rural patients with co-occurring disorders: The gap in managing addiction. Psychiatric Services, 72(8), 935–942. 10.1176/appi.ps.202000312 [DOI] [PubMed] [Google Scholar]
- Stokols D (1992). Establishing and maintaining healthy environments: Toward a social ecology of health promotion. American Psychologist, 47(1), 6–22. 10.1037//0003-066x.47.1.6 [DOI] [PubMed] [Google Scholar]
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2021). Medication-assisted treatment. https://www.samhsa.gov/medication-assisted-treatment. [PubMed] [Google Scholar]
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2023, 29 March). Removal of DATA Waiver (X-Waiver) Requirement. https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement [Google Scholar]
- Tofighi B, Williams AR, Chemi C, Suhail-Sindhu S, Dickson V, & Lee JD (2019). Patient barriers and facilitators to medications for opioid use disorder in primary care. Substance Use & Misuse, 54(14), 2409–2419. 10.1080/10826084.2019.1653324 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Truong C, Krawczyk N, Dejman M, Marshall-Shah S, Tormohlen K, Agus D, & Bass J (2019). Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City. Addictive Behaviors, 93, 14–19. 10.1016/j.addbeh.2019.01.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
